The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA) for prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback